HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Ashley Clayton, hereby consent to be cited in the Acknowledgements section of this manuscript.

HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Caroline Brackett, hereby consent to be cited in the Acknowledgements section of this manuscript.

Duke Human Vaccine Institute, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, _____, hereby consent to be cited in the Acknowledgements section of this manuscript.

David Beaumont

[Signature]

Duke

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Dalene de Swardt_____, hereby consent to be cited in the Acknowledgements section of this manuscript.

Previous employee at CHIL

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Ellen Shrontz, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Jack Heptinstall, hereby consent to be cited in the Acknowledgements section of this manuscript.

Duke Human Vaccine Institute, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Kristy Long, hereby consent to be cited in the Acknowledgements section of this manuscript.

Duke University Medical Center

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, LAUREN YOUNG, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

SCHARP, FHCRC

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, LISA BUNTS, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

FHCRC / HIV VACCINE TRIALS NETWORK (HVTN)
STATISTICAL + DATA MANAGEMENT CENTER (SDMC)

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Lu Zhang, hereby consent to be cited in the Acknowledgements section of this manuscript.

Duke Human Vaccine Institute, Departments of Surgery, Duke University School of Medicine, Durham, NC, USA

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Margaret Mazyambe, hereby consent to be cited in the Acknowledgements section of this manuscript.

Nhute
[Signature]

Cape Town HVTN Immunology Laboratory
[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Marcella Sarzotti-Kelsoe, hereby consent to be cited in the Acknowledgements section of this manuscript.

Marcella Sarzotti-Kelsoe, Ph.D.
Research Professor of Immunology
Associate Professor of Surgery
Director, Central QAU for Duke Vaccine Immunogenicity Programs
and for Center for AIDS Research
Duke University Medical Center
2812 Erwin Rd., Suite 301, Erwin Terrace II
Durham, NC 27705 USA
Tel. (919) 684-6373
FAX (919) 681-7766

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Sheetal Sawant , hereby consent to be cited in the Acknowledgements section of this manuscript.

11/21/2019

[Signature]

Duke Human Vaccine Institute, Department of Surgery, Duke University School of Medicine, Durham, NC, USA

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Yong Lin, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Sara Thiebaud, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

FHCRC / HVTN SDMC
[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Zinhle Mgaga, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

Cape Town HVTN Immunology Laboratory.
[Affiliation]

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Saleha Omarjee, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature] Somarjee

[Affiliation] Cape Town HVTN Immunology Laboratory

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Nikki Schuller, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

[Affiliation] Cape Town HVTN Immunology Laboratory

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, STEPHANY WILCOX, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature]

[Affiliation] CAPE TOWN HVTN IMMUNOLOGY LABORATORY

HIV VACCINE
TRIALS NETWORK

Re: Consent to be acknowledged in manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial (corresponding author: Linda-Gail Bekker)

To Whom It May Concern,

In support of submission of the manuscript summarizing results of the HVTN 602/Aeras A-042 clinical trial, currently entitled "**A phase 1b study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa**," I, Shamiska Rohith, hereby consent to be cited in the Acknowledgements section of this manuscript.

[Signature] Rohith

[Affiliation] Cape Town HVTN Immunology Laboratory